KANJINTI

PeakmAb

trastuzumab-anns

BLASINGLE-DOSEVIAL

Approved

Jun 2019

Lifecycle

Peak

Competitive Pressure

30/100

Mechanism of Action

HER2/Neu/cerbB2 Antagonists

Pharmacologic Class:

HER2/neu Receptor Antagonist

Company

THOUSAND OAKS, CA

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers